HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs. gemcitabine + placebo in patients with platinum-resistant epithelial ovarian cancer

Lukas C. Amler,S. Makhija,Thomas Januario,Ursula A. Matulonis,Andreas Strauss,Don S. Dizon,Mark X. Sliwkowski,M Dolezal,B. Tong,Virginia E. Paton

HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs. gemcitabine + placebo in patients with platinum-resistant epithelial ovarian cancer

2008

Lukas C. Amler
S. Makhija
Thomas Januario
Ursula A. Matulonis
Andreas Strauss
Don S. Dizon
Mark X. Sliwkowski
M Dolezal
B. Tong
Virginia E. Paton

5552 Background: Pertuzumab (P) is a humanized monoclonal antibody that inhibits HER2 heterodimerization. A randomized phase II trial (N=130) of pertuzumab + gemcitabine vs. gemcitabine + placebo i...

Keywords:

Ovarian cancer
Gene expression
Phases of clinical research
Placebo
Gemcitabine
Pertuzumab
Cancer research
Oncology
Pathology
Internal medicine
Medicine
epithelial ovarian cancer
in patient
platinum resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations